CN116096369A - 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用 - Google Patents

布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用 Download PDF

Info

Publication number
CN116096369A
CN116096369A CN202180053967.4A CN202180053967A CN116096369A CN 116096369 A CN116096369 A CN 116096369A CN 202180053967 A CN202180053967 A CN 202180053967A CN 116096369 A CN116096369 A CN 116096369A
Authority
CN
China
Prior art keywords
compound
formula
ray powder
mixture
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053967.4A
Other languages
English (en)
Inventor
李金晶
江涛涛
曾振亚
杨菡
陈曦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Original Assignee
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze River Pharmaceutical Group Co Ltd, Shanghai Haiyan Pharmaceutical Technology Co Ltd filed Critical Yangtze River Pharmaceutical Group Co Ltd
Publication of CN116096369A publication Critical patent/CN116096369A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00

Abstract

本发明提供了布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用，具体地提供了(R)‑6‑((1‑丙烯酰基哌啶‑3‑基)氨基)‑7‑氟‑4‑((2‑氟‑4‑吗啉代苯基)氨基)‑1,2‑二氢‑3H‑吡咯并[3,4‑c]吡啶‑3‑酮的两种晶型、其制备方法和应用。本发明提供的两种晶型具有较好的稳定性、不易吸湿、改善的溶解性和药代动力学特征，且制备方法稳定，能够进行大规模生产。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN202180053967.4A 2020-09-01 2021-09-01 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用 Pending CN116096369A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020109030402 2020-09-01
CN202010903040 2020-09-01
PCT/CN2021/115856 WO2022048551A1 (zh) 2020-09-01 2021-09-01 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用

Publications (1)

Publication Number Publication Date
CN116096369A true CN116096369A (zh) 2023-05-09

Family

ID=80491613

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053967.4A Pending CN116096369A (zh) 2020-09-01 2021-09-01 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN116096369A (zh)
WO (1) WO2022048551A1 (zh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2516434T1 (sl) * 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
CN107021963A (zh) * 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
JP6922085B2 (ja) * 2017-09-28 2021-08-18 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． ４，６，７−三置換 １，２−ジヒドロピロロ［３，４−ｃ］ピリジン／ピリミジン−３−オン誘導体及びその使用
WO2020187267A1 (zh) * 2019-03-18 2020-09-24 上海海雁医药科技有限公司 Btk抑制剂及其药学上可接受的盐和多晶型物及其应用

Also Published As

Publication number Publication date
WO2022048551A1 (zh) 2022-03-10

Similar Documents

Publication Publication Date Title
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CN107531678B (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
AU2011270890A1 (en) Polymorphs of OSI-906
CN112424202B (zh) 抑制cdk4/6活性化合物的晶型及其应用
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
EP3476841A1 (en) Crystals of aniline pyrimidine compound serving as egfr inhibitor
CN112334469B (zh) Btk抑制剂及其药学上可接受的盐和多晶型物及其应用
CN110950847A (zh) 氘代azd9291化合物的新晶型及其用途
CN116096369A (zh) 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
CN114315837B (zh) 一种erk抑制剂的结晶形式及其制备方法
CN113278017B (zh) 取代吲唑类化合物、制备方法、应用和包含其的组合物
CN111566101B (zh) Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
JP2023543080A (ja) ピロロ複素環系誘導体の結晶及びその製造方法
CN111601791B (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
JP6961675B2 (ja) Ｔｔｋ阻害剤の固体形態
WO2023041061A1 (zh) 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
WO2024067085A1 (zh) 一种细胞周期蛋白依赖性激酶(cdk4/6)抑制剂的枸橼酸盐、其晶型、制备方法和用途
CN115843298B (zh) 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型
CN111606891B (zh) (1,1,1-三氯-2)氨基甲酸酯类衍生物及其制备方法和应用
WO2023125947A1 (zh) 四氢异喹啉类化合物的可药用盐、晶型及其用途
KR20240007187A (ko) 이미다졸리디논류 화합물의 다형체, 제조 방법 및 이의 용도
CN117794913A (zh) 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用
CN115232124A (zh) 一种atx抑制剂的结晶形式及其制备方法
CN114907343A (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
CN117915919A (zh) 氮杂芳环类化合物及其药学上可接受的盐的多晶型物、药物组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination